Bli medlem
Bli medlem

Du är här

2021-11-10

Nanexa publishes interim report for January – September 2021

Substantial orders and pause in the NEX-18 study

Significant events during the third quarter 2021

  • In July, Nanexa completed the fully underwritten rights issue decided in June 2021, supported by the authorisation from the Annual General Meeting, which raised SEK 107 million after issue costs for the company.
  • The European Patent Office (EPO) announced in July its intention to grant a European patent for Nanexa's PharmaShell® technology.
  • Nanexa received two orders for the surface treatment of a large number of sensors for the detection of radioactive isotopes of the noble gas xenon, from two US customers for a total value of approximately SEK 1.7 million.
  • Nanexa decided at the end of September to pause the inclusion of patients in the company's Phase I trial of NEX-18, a depot formulation of 5-azacitidine, due to moderate skin reactions at the injection site. An investigation into the cause was initiated with the clinics participating in the study.

Significant events after the end of the period

  • Nanexa received a decision from the Swedish Financial Supervisory Authority to pay a penalty of SEK 1,000,000 in relation to an incident that occurred in 2017.
  • Nanexa signed an additional Material Transfer and Feasibility Study Agreement with one of its existing customers for the evaluation of the PharmaShell® technology with a specific biological drug substance.
  • Additional preclinical studies were initiated in October to investigate the cause of the moderate skin reactions seen in the company's Phase I study of NEX-18, a depot formulation of 5-azacitidine.

Summary of the reporting period 1 July – 30 September 2021

  • Turnover amounted to: TSEK 826 (530)
  • Operating profit (EBIT) amounted to: TSEK -7,857 (-3,814)
  • Profit after tax amounted to: TSEK -7,904 (-3,894)
  • Earnings per share amounted to: SEK -0.18 (-0.18)
  • Cash flow for the period amounted to: TSEK 91,203 (-8,098)
  • Cash and cash equivalents at end of period: TSEK 119,799 (25,990)

Summary of the reporting period 1 January – 30 September 2021

  • Turnover amounted to: TSEK 1,704 (1,819)
  • Operating profit (EBIT) amounted to: TSEK -22,776 (-13,713)
  • Profit after tax amounted to: TSEK -22,912 (-13,914)
  • Earnings per share amounted to: SEK -0.75 (-0.71)
  • Cash flow for the period amounted to: TSEK 107,108 (14,612)
  • Cash and cash equivalents at end of period: TSEK 119,799 (25,990)

Figures in brackets refer to the corresponding period in the previous year.

For additional information, please contact:


David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
Erik Penser Bank is the company’s Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)


Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential for a number of medical substance types and indications. Within the framework of PharmaShell®, Nanexa devlops its own products and has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments


Nanexa Interim Report Jan Sep 2021

Författare MFN